FailedDiscontinued

UGN-301

Non-muscle invasive bladder cancer (NMIBC)

URGNUroGen Pharma

Expected catalystTBA

Catalyst overview

Event details

Drug or asset: UGN-301
Development stage: Failed
Event type: Discontinued
Indication: Non-muscle invasive bladder cancer (NMIBC)

Research summary

What is being tracked?

This catalyst tracks a Failed discontinued for UGN-301 in Non-muscle invasive bladder cancer (NMIBC). The expected timing is based on the latest available company guidance and may change.

Development notes

3/10/25- Completed enrollment. 3/26/25- Presented results of Ph1 dose escalation study at AUA '25. Presentation of data from combo arms in H2 2025. 11/06/25:- Development discontinued after Ph1 dose escalation; license with Agenus terminated after wind-down.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Source URL not provided